Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar jmacn22 (70.17) Submitted: 2/5/2009 1:04:25 PM : Underperform Start Price: $24.46 ACOR Score: +66.09

Underperform

Featured Broker Partners


Advertisement